Head-to-head evidence
Aclidinium bromide vs Glycopyrrolate/formoterol fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Covis Pharma
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo and used trough FEV1, an accepted clinical lung-function endpoint for COPD, as its primary outcome at 12 and 28 weeks. Aclidinium showed higher reported mean FEV1 values at both time points, but because statistical significance for the primary comparisons is not reported, the result is considered unclear rather than definitively met.
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Glycopyrrolate/formoterol fumarate's landscape